SK2292003A3 - Tricyclic antitumor compounds being farnesyl protein transferase inhibitors - Google Patents

Tricyclic antitumor compounds being farnesyl protein transferase inhibitors Download PDF

Info

Publication number
SK2292003A3
SK2292003A3 SK229-2003A SK2292003A SK2292003A3 SK 2292003 A3 SK2292003 A3 SK 2292003A3 SK 2292003 A SK2292003 A SK 2292003A SK 2292003 A3 SK2292003 A3 SK 2292003A3
Authority
SK
Slovakia
Prior art keywords
compound
mmol
solution
preparation
compounds
Prior art date
Application number
SK229-2003A
Other languages
English (en)
Slovak (sk)
Inventor
George F Njoroge
Bancha Vibulbhan
Alan B Cooper
Timothy Guzi
Dinanath F Rane
Keith P Minor
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Bama Santhanam
Patrick A Pinto
Hugh Y Zhu
Kartik M Keertikar
Carmen S Alvarez
Robert W Bishop
James Wang
Jagdish A Desai
John J Baldwin
Ge Li
Chia-Yu Huang
Ray A James
Original Assignee
Schering Corp
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp
Publication of SK2292003A3 publication Critical patent/SK2292003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK229-2003A 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors SK2292003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30
PCT/US2001/026792 WO2002018368A1 (en) 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Publications (1)

Publication Number Publication Date
SK2292003A3 true SK2292003A3 (en) 2003-08-05

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
SK229-2003A SK2292003A3 (en) 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Country Status (27)

Country Link
US (1) US20020198216A1 (de)
EP (1) EP1313725B1 (de)
JP (1) JP2004513885A (de)
KR (1) KR20030034161A (de)
CN (1) CN100384837C (de)
AR (1) AR033680A1 (de)
AT (1) ATE359281T1 (de)
AU (2) AU2001288451C1 (de)
BR (1) BR0113675A (de)
CA (1) CA2420673A1 (de)
CO (1) CO5640109A2 (de)
DE (1) DE60127846T2 (de)
EC (1) ECSP034494A (de)
ES (1) ES2284686T3 (de)
HK (1) HK1054548B (de)
HU (1) HUP0302942A3 (de)
IL (1) IL154528A0 (de)
MX (1) MXPA03001849A (de)
NO (1) NO20030918L (de)
NZ (1) NZ524246A (de)
PE (1) PE20020486A1 (de)
PL (1) PL361103A1 (de)
RU (1) RU2293734C9 (de)
SK (1) SK2292003A3 (de)
TW (1) TWI268280B (de)
WO (1) WO2002018368A1 (de)
ZA (1) ZA200301545B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
ATE554756T1 (de) 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
JP2005531488A (ja) * 2001-10-09 2005-10-20 ザ・ユニバーシティ・オブ・シンシナティ 甲状腺癌を処置するためのegf受容体阻害剤
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
EP1453513A1 (de) * 2001-12-03 2004-09-08 Schering Corporation Verwendung von fpt inhibitoren und mindestens zwei anderen ant-krebsmitteln zur krebsbehandlung
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004094409A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
EP1628631A2 (de) * 2003-06-05 2006-03-01 Achkar, Charles C. Verfahren zur behandlung von hyperproliferativen zellerkrankungen
US20070036795A1 (en) * 2003-06-09 2007-02-15 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
RU2006106768A (ru) * 2003-08-07 2007-09-20 Шеринг Корпорейшн (US) Новые ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
WO2006069208A2 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
RU2361587C1 (ru) * 2008-02-14 2009-07-20 Михаил Владимирович Кутушов Лекарственное средство для лечения онкологических заболеваний
EP2313091A4 (de) * 2008-07-14 2012-04-04 Univ Kingston Pharmazeutische zusammensetzungen mit ret-hemmern und verfahren zur behandlung von krebs
EP3989956A1 (de) * 2019-06-28 2022-05-04 Anhui Ronghang Biotech Development Co., Ltd. Zusammensetzungen und verfahren zur behandlung von hepatitis-b-virus-infektionen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
NZ238629A (en) * 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
SK7582001A3 (en) * 1998-12-18 2002-03-05 Schering Corp Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition

Also Published As

Publication number Publication date
PL361103A1 (en) 2004-09-20
WO2002018368A1 (en) 2002-03-07
HUP0302942A2 (hu) 2003-12-29
NO20030918D0 (no) 2003-02-27
ES2284686T3 (es) 2007-11-16
NZ524246A (en) 2004-11-26
AR033680A1 (es) 2004-01-07
MXPA03001849A (es) 2003-06-04
PE20020486A1 (es) 2002-06-14
US20020198216A1 (en) 2002-12-26
ATE359281T1 (de) 2007-05-15
IL154528A0 (en) 2003-09-17
TWI268280B (en) 2006-12-11
DE60127846D1 (en) 2007-05-24
NO20030918L (no) 2003-04-29
EP1313725B1 (de) 2007-04-11
KR20030034161A (ko) 2003-05-01
EP1313725A1 (de) 2003-05-28
CA2420673A1 (en) 2002-03-07
AU2001288451C1 (en) 2008-03-06
AU2001288451B2 (en) 2007-05-24
CN1471524A (zh) 2004-01-28
CN100384837C (zh) 2008-04-30
BR0113675A (pt) 2003-06-24
ZA200301545B (en) 2004-06-22
AU8845101A (en) 2002-03-13
JP2004513885A (ja) 2004-05-13
CO5640109A2 (es) 2006-05-31
HK1054548B (en) 2007-10-18
RU2293734C9 (ru) 2007-10-10
HK1054548A1 (en) 2003-12-05
DE60127846T2 (de) 2008-03-06
ECSP034494A (es) 2003-04-25
HUP0302942A3 (en) 2007-02-28
RU2293734C2 (ru) 2007-02-20

Similar Documents

Publication Publication Date Title
ES2284686T3 (es) Compuestos antitumorales triciclicos que son inhibidores de la proteina transferasa de farnesilo.
US20030229099A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
DE69831937T2 (de) Bicyclische protein-farnesyl-transferase inhibitoren
US20040006087A1 (en) Method of treating cancer using FPT inhibitors and antineoplastic agents
US7342016B2 (en) Farnesyl protein transferase inhibitors as antitumor agents
AU2001288451A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
AU2006207300A1 (en) Substituted triazole derivatives as oxytocin antagonists
CN113348165B (zh) 用于治疗过度增殖性疾病的1,2,4-三嗪-3(2h)-酮化合物
JP2005525356A5 (de)
EP0989983B1 (de) Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung
WO2005014577A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
JP2002533336A (ja) 三環式ファルネシルタンパク質トランスフェラーゼインヒビター
US20060211706A1 (en) Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
US5945430A (en) Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase
CN114555603B (zh) 制备作为食欲素受体调节剂的(2h-1,2,3-三唑-2-基)苯基化合物的改进的合成方法
AU2007202115A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
HK40060627B (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors

Legal Events

Date Code Title Description
FC9A Refused patent application